Get notified when PMVP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Mandatory Exercise (new) — Warrant holders are forced to exercise within 30 days of an FDA NDA acceptance or lose their warrants, creating potential forced capital calls and share overhang.
- Exercise Price Reset (new) — Warrant exercise price may be reduced upon NDA acceptance, increasing the number of shares issuable and diluting existing shareholders.
PMV Pharmaceuticals files preliminary prospectus for common stock and warrant offering, terms not yet set
Filed August 31, 2026 · ~1 min read
Key Changes
-
high
Offering consists of common stock (or pre-funded warrants) each sold with a common stock warrant; share count, warrant coverage, and price are left blank in this preliminary prospectus.
The Offering verify on EDGAR → -
high
Warrants include a price reset tied to an NDA Acceptance Announcement and a mandatory exercise period if the FDA accepts the NDA, potentially forcing exercise or forfeiture.
The Offering verify on EDGAR → -
high
Net proceeds, together with $79.4 million cash as of June 30, 2026, are intended to fund late-stage development, regulatory submission, and commercialization preparation for rezatapopt.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ESTC 10-Q) is open in full — no account needed.
Partner
Trade PMVP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify